Kroeger Christopher A. sold $5.4M of MPLT

Kroeger Christopher A. (Chief Executive Officer) sold 147,639 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $36.87 ($36.00–$37.96, $5.44M total) across 7 trades over 2026-07-15 to 2026-07-17.

Original reporting
SEC EDGAR · Kroeger Christopher A.
Published Jul 18, 2026, 1:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 18, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The CEO’s open-market sale is a sentiment input for traders monitoring insider behavior, but it does not change the company’s disclosed fundamentals in this text.

02

Market read

Traders may reassess near-term sentiment around MPLT based on CEO selling size and timing, but there is no accompanying operational update here.

03

What to watch

The filing does not state a reason for the sale and explicitly notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty rather than confirm bearish intent.

Relevance 6/10Novelty 5/10Timing: after-hours filing timestamp (filed 2026-07-17T21:46:47-04:00) covering sales from 2026-07-15 to 2026-07-17

Background

The article is an SEC Form 4 insider transaction disclosure for MapLight Therapeutics, Inc.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight Therapeutics CEO Christopher A. Kroeger sold about 147,639 shares in open-market trades for roughly $5.44M, per Form 4.

Expected impact

Likely limited, short-lived impact unless follow-on filings or company-specific news emerge.

Evidence & confidence

The filing is a primary-source Form 4 showing sale size and price range, but it provides no stated reason, no 10b5-1 plan, and no accompanying operational or guidance change.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management, especially given multiple small trades across consecutive days, so it may not signal deteriorating fundamentals.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the Form 4 insider sale by its CEO.

  • Christopher A. Kroeger

    CEO and officer/director who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in